Edwards Lifesciences (EW) · Medical Devices
Edwards Lifesciences Q2 2026 earnings: summary, key numbers & outlook
Results filed 23 Jul 2026 · Quarter ended 30 Jun 2026
Official transcript (PDF) ↗Press release ↗Investor relations ↗
Summaries and transcripts are machine-generated and can contain errors.
In brief
Edwards' mitral and tricuspid therapies grew 47.3% on PASCAL and EVOQUE adoption, ahead of expected fourth-quarter U.S. approvals for PASCAL in tricuspid and for next-generation PASCAL.
Edwards' growth now comes from several structural heart platforms rather than one. TAVR demand was supported by evidence for treating aortic stenosis earlier and by long-term SAPIEN durability data. The company also benefited from a competitor's exit in Q2 2025. The mitral and tricuspid business kept scaling with PASCAL and EVOQUE, and SAPIEN M3 is in a measured launch. Growth rates were similar in the U.S. and outside it, and average selling prices were stable globally.
Management is steering toward a portfolio of TAVR, mitral, tricuspid and surgical platforms and a longer-term goal of about 10% annual sales growth. Near-term catalysts include fourth-quarter approvals, TCT data from the PROGRESS and CLASP IITR trials, and a CMS final decision memo on TAVR coverage expected in September. The tension is that much of the next leg of growth depends on regulatory, reimbursement and trial outcomes that Edwards does not control.
Key numbers
- Net sales · GAAP
- $1.74 billion
- Net income attributable to Edwards · GAAP
- $241.9M
- Diluted EPS · GAAP
- $0.42
- Adjusted EPS · non-GAAP
- $0.78
- Gross profit margin · GAAP
- 77.5%
- Operating profit margin · GAAP
- 29.5%
up 13.6%; 12.5% in constant currency
down from $333.2 a year ago
down from $0.56 a year ago
up from $0.67 a year ago
consistent with the same period last year
up from 26.8% a year ago
| Segment or metric | Value | Change |
|---|---|---|
| TAVR sales | $1.26 billion | up 11.3%; 10.5% in constant currency |
| TMTT sales | $195.9 million | up 47.3%; 44.8% in constant currency |
| Surgical sales | $284 million | up 6.5%; 5.0% in constant currency |
| United States sales | $1.0B | up 12.8% |
Where each number comes from
- Net sales: “Q2 sales grew 13.6% to $1.74 billion1, constant currency2 sales grew 12.5%”
- Net income attributable to Edwards: “Net loss attributable to noncontrolling interest | (0.5) | (1.7) | (0.5) | (3.3) Net income attributable to Edwards Lifesciences Corporation | $241.9 | $333.2 | $622.6 | $691.2”
- Diluted EPS: “Diluted: Continuing operations | $0.42 | $0.57 | $1.07 | $1.20 Discontinued operations | $— | $(0.01) | $— | $(0.02) Diluted earnings per share | $0.42 | $0.56”
- Adjusted EPS: “Adjusted | $1,741.0 | 77.6% | $522.7 | 30.0% | $— | $(3.3) | $447.9 | $0.78 | 18.6%”
- Gross profit margin: “For the quarter, gross profit margin was 77.5%, or 77.6% adjusted, consistent with the same period last year”
- Operating profit margin: “Operating profit margin in the second quarter was 29.5%, or 30.0% adjusted.”
- TAVR sales: “Q2 TAVR sales grew 11.3% to $1.26 billion1; constant currency2 sales grew 10.5%”
- TMTT sales: “Second quarter TMTT sales of $195.9 million increased 47.3% compared to the prior year, or 44.8% on a constant currency basis.”
- Surgical sales: “In Surgical, second quarter global sales of $284 million increased 6.5% compared to the prior year, or 5.0% on a constant currency basis”
- United States sales: “United States | $1,003.5 | $889.7 | $113.8 | 12.8% | $— | $889.7 | 12.8%”
Copied from the press release ↗ and other documents in the SEC filing ↗. A figure is published only if its sentence is in those documents.
| From the filing | Q2 2026 | vs year ago | vs last quarter |
|---|---|---|---|
| Revenue | $1.7B | +13.6% | +5.6% |
| Operating income | $513.2M | +24.8% | +7.5% |
| Net income | $241.9M | −27.4% | −36.5% |
| Diluted EPS | $0.42 | −25.0% | −36.4% |
| Free cash flow | $585.0M | +142.8% | — |
| Gross margin | 77.5% | +0.0 pts | −0.5 pts |
| Operating margin | 29.5% | +2.7 pts | +0.5 pts |
Calculated by code from XBRL, not by the model.
Outlook
| Metric | Period | Outlook |
|---|---|---|
| Total sales | third quarter of 2026 | between $1.63 and $1.71 billion |
| Adjusted EPS | third quarter of 2026 | $0.71 to $0.77 |
| Total company constant currency sales growth | full year 2026 | 10% to 11% |
| Total company sales | full year 2026 | $6.6 billion to $6.9 billion |
| TAVR constant currency sales growth | full year 2026 | 8% to 9% |
| TMTT sales | full year 2026 | $760 to $780 million |
| Adjusted EPS | full year 2026 | $2.95 to $3.05 |
| Gross profit margin | full year 2026 | 78% to 79% |
| Operating profit margin | full year 2026 | 28% to 29% |
| Effective tax rate excluding special items | full year 2026 | 16% to 19% |
| R&D expense as a percentage of sales | 2026 | approximately 17% |
Key takeaways
Mitral and tricuspid is a scaling second platform
TMTT sales of $195.9 million rose 47.3%, with mitral and tricuspid procedure growth in the double digits globally. Edwards says PASCAL adoption is increasing and EVOQUE continues to scale in the U.S. and Europe.
TAVR demand rests on earlier treatment and durability
Edwards points to evidence supporting proactive management of severe aortic stenosis and long-term SAPIEN durability data. Its competitive position rose modestly in both the U.S. and Europe, and average selling prices were stable globally.
Fourth-quarter approvals and TCT data are key catalysts
Edwards expects Q4 approvals of PASCAL for tricuspid in the U.S. and of next-generation PASCAL with Capture Clarity in the U.S. and Europe. It also expects PROGRESS and CLASP IITR results at TCT, which test the moderate aortic stenosis opportunity and tricuspid evidence.
CMS TAVR coverage decision is due in September
CMS is reconsidering the National Coverage Determination for TAVR, with a final decision memo expected in September. Edwards says the update could advance TAVR for Medicare beneficiaries with aortic stenosis.
SAPIEN M3 and ECLIPTIS launches are deliberately measured
Edwards is opening new SAPIEN M3 centers steadily as sites build experience. It is also planning a measured rollout later this year of ECLIPTIS, its newly U.S.-approved surgical left atrial appendage system.
Charts
Fourth quarter worked out from the annual figure.
Data
| Q4 2024 | $1.4B |
| Q1 2025 | $1.4B |
| Q2 2025 | $1.5B |
| Q3 2025 | $1.6B |
| Q4 2025 | $1.6B * |
| Q1 2026 | $1.6B |
| Q2 2026 | $1.7B |
| Q3 2026 | $1.7B |
Data
| Q4 2024 | $0.65 |
| Q1 2025 | $0.61 |
| Q2 2025 | $0.56 |
| Q3 2025 | $0.50 |
| Q1 2026 | $0.66 |
| Q2 2026 | $0.42 |
| Q3 2026 | $0.53 |
Fourth-quarter EPS appears once the press release is read; filings report it only for the full year.
Data
| Q4 2024 | 22.6% |
| Q1 2025 | 27.9% |
| Q2 2025 | 26.8% |
| Q3 2025 | 19.8% |
| Q4 2025 | 9.6% |
| Q1 2026 | 29.0% |
| Q2 2026 | 29.5% |
| Q3 2026 | 17.4% |
Data
| Q4 2024 | -$177.3M |
| Q1 2025 | $224.4M |
| Q2 2025 | $240.9M |
| Q3 2025 | $516.2M |
| Q4 2025 | $353.5M |
| Q1 2026 | -$21.1M |
| Q2 2026 | $585.0M |
| Q3 2026 | $506.7M |
Operating cash flow minus capital expenditure, from cash flow statements.
Questions
What is driving Edwards' TAVR growth?
Edwards cites evidence supporting proactive management of severe aortic stenosis, long-term SAPIEN durability data and a competitor's exit in Q2 2025. TAVR sales grew 11.3%, with similar growth rates in the U.S. and outside it.
How is the mitral and tricuspid business doing?
TMTT sales were $195.9 million, up 47.3%, with double-digit procedure growth globally. Edwards says PASCAL adoption is rising and EVOQUE is scaling in the U.S. and Europe.
What product and regulatory milestones does Edwards expect next?
In Q4 it expects approvals of PASCAL for tricuspid in the U.S. and of next-generation PASCAL with Capture Clarity in the U.S. and Europe. It also expects PROGRESS and CLASP IITR results at TCT and a CMS final decision memo on the TAVR coverage determination in September.
How is Edwards positioned against competitors in TAVR?
Edwards says its competitive position increased modestly year over year in both the U.S. and Europe. It credits adoption of SAPIEN 3 Ultra RESILIA, the SAPIEN durability data and a competitor's exit in Q2 2025.
How did Edwards change its 2026 outlook?
It raised total constant currency sales growth guidance to 10% to 11% from 9% to 11%, TAVR growth to 8% to 9%, and TMTT sales to $760 to $780 million. It reaffirmed adjusted EPS of $2.95 to $3.05 and expects gross margin at the lower end of its 78% to 79% range.
Documents
From Edwards Lifesciences investor relations
SEC filing